Search & Analyze

Glenmark Pharmaceuticals Ltd.

HealthcarePharmaceuticals & Drugs

www.glenmarkpharma.com BSE: 532296NSE: GLENMARK

₹2,462.00BSE2.04%

07 Sep, 4:01 PM

₹2,462.00

₹69.48K Cr

38.65

6.34

14.10%

₹2,471.50

₹2,412.75

₹2,536.85

₹1,794.00

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,899.80	37.69	4,55,825.66	0.84	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,305.00	84.45	2,47,018.51	0.32	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,913.00	85.68	1,86,874.73	0.77	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,155.00	25.53	1,15,211.69	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,395.95	33.46	1,12,773.00	0.93	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,868.25	92.32	1,00,943.83	0.11	362.07	123.94%	2,026.31	29.10%	18.20
LUPIN LTD. LUPIN	2,105.00	17.41	96,254.46	0.86	1,416.98	16.01%	8,276.89	32.04%	28.86
Glenmark Pharmaceuticals Ltd. GLENMARK	2,462.00	38.65	69,483.71	0.10	482.83	927.88%	4,018.48	23.10%	20.35

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Sep 2022	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	3,017.93	3,062.95	3,244.19	3,433.80	3,387.55	3,256.21	3,264.44	6,046.87	3,900.62	3,770.59	4,018.48
Expenses	2,538.96	2,558.61	2,655.97	2,831.88	2,787.32	2,695.18	2,683.92	3,687.32	3,030.87	3,007.99	3,213.69
	478.98	504.34	588.21	601.91	600.23	561.03	580.52	2,359.55	869.75	762.60	804.80
	15.87%	16.47%	18.13%	17.53%	17.72%	17.23%	17.78%	39.02%	22.30%	20.22%	20.03%
	86.35	326.38	31.49	39.42	31.13	-361.13	-296.79	-1,184.49	-139.87	-184.32	65.76
Interest	82.94	148.56	39.58	48.48	52.29	66.71	58.23	66.46	41.43	42.60	54.00
	145.77	151.34	117.79	120.28	122.74	125.21	129.93	141.20	154.45	147.91	173.17
	336.62	530.83	462.33	472.57	456.33	7.97	95.58	967.40	534.00	387.77	643.39
	48.97%	333.34%	26.41%	24.99%	23.73%	45.02%	50.85%	36.90%	24.49%	22.29%	24.96%
	260.44	-1,218.28	340.27	354.21	347.96	4.65	46.87	610.35	403.21	301.41	482.92
	9.23	-43.17	12.06	12.55	12.33	0.16	1.66	21.63	14.29	10.68	17.11

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	27,804.50	28,219.34	27,709.01	28,707.10	34,618.18
	12,304.90	11,583.24	11,813.10	13,321.74	16,982.51
EXPENDITURE :
Increase/Decrease in Stock	-11.14	-240.66	-195.62	-213.93	-610.64
Raw Material Consumed	4,323.22	4,445.04	4,547.62	4,501.30	5,297.71
Power & Fuel Cost	200.64	111.75	124.00	131.40	134.13
Employee Cost	2,447.42	2,600.78	2,868.14	3,022.06	3,577.85
Other Manufacturing Expenses	784.63	633.51	1,012.86	767.88	763.17
General and Administration Expenses	1,264.86	1,212.13	1,313.59	1,457.32	1,758.14
Selling and Distribution Expenses	896.31	1,137.20	892.72	1,270.52	1,431.79
Miscellaneous Expenses	78.68	48.49	54.46	33.81	57.94
	9,984.60	9,948.23	10,617.77	10,970.36	12,410.09
Operating Profit (Excl OI)	2,320.30	1,635.01	1,195.33	2,351.38	4,572.42
	166.67	288.90	839.99	113.72	460.62
	2,486.97	1,923.91	2,035.33	2,465.10	5,033.04
Interest	298.10	349.04	515.97	207.07	208.73
PBDT	2,188.87	1,574.87	1,519.36	2,258.04	4,824.31
	486.72	569.17	581.91	486.01	573.48
Profit Before Taxation & Exceptional Items	1,702.16	1,005.70	937.45	1,772.03	4,250.83
Exceptional Income / Expenses	-260.91	-765.85	-900.95	-372.82	-2,266.08
	1,441.25	239.84	36.50	1,399.21	1,984.75
Provision for Tax	447.60	329.40	1,867.35	352.07	622.79
	993.65	-89.56	-1,830.85	1,047.14	1,361.95
Extra items				0.00	0.00
Minority Interest	-51.94	-80.16	-68.15	-0.05	-0.10
Consolidated Net Profit	941.71	297.25	-1,501.67	1,047.10	1,361.85
Profit Balance B/F	7,233.62	9,210.91	9,457.04	7,870.45	8,798.54
Appropriations	8,175.33	9,508.15	7,955.37	8,917.55	10,160.39
Equity Dividend %	250.00%	250.00%	250.00%	250.00%	250.00%
	33.37	10.53	-53.21	37.11	48.26
Adjusted EPS	33.37	10.53	-53.21	37.11	48.26

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	28.22	28.22	28.22	28.22	28.22
Share Warrants & Outstandings	16.30	17.62	18.23	9.06	34.01
Total Reserves	9,042.13	9,428.09	7,801.48	8,812.16	10,449.88
Reserve excluding Revaluation Reserve	9,042.13	9,428.09	7,801.48	8,812.16	10,449.88
Revaluation reserve			0.00
	9,086.65	9,473.92	7,847.93	8,849.44	10,512.11
Minority Interest	351.47	365.34	-0.38	-0.37	-0.32
Unsecured Loans	2,571.74	3,852.14		512.70
Deferred Tax Assets / Liabilities	-1,654.63	-1,805.40	-1,049.44	-1,065.52	-1,245.38
Other Long Term Liabilities	352.50	574.71	692.21	662.17	2,841.81
Long Term Provisions					176.61
Total Non-Current Liabilities	1,269.61	2,621.45	-357.23	109.35	1,773.05
Trade Payables	2,288.66	2,000.43	2,535.93	3,051.20	3,743.87
Other Current Liabilities	1,446.27	1,605.31	1,517.23	436.17	1,467.94
Short Term Borrowings	370.00	350.00	833.36	1,681.50
Short Term Provisions	584.50	590.51	932.08	798.16	1,164.62
Total Current Liabilities	4,689.43	4,546.24	5,818.59	5,967.02	6,376.43
Total Liabilities	15,397.17	17,565.76	13,308.90	14,925.45	18,661.26
Gross Block	10,213.47	10,359.59	9,619.64	10,364.92	12,071.85
Less: Accumulated Depreciation	4,326.23	4,937.83	5,409.48	5,878.10	6,157.31
Net Block	5,887.25	5,421.76	4,210.16	4,486.83	5,914.54
Capital Work in Progress	921.09	1,065.82	419.32	541.99	427.87
Non Current Investments	49.62	44.57	789.66	56.36	42.36
Long Term Investment	49.62	44.57	789.66	56.36	42.36
Long Term Loans & Advances	161.38	180.80	211.70	242.74	492.67
Other Non Current Assets	6.70	3.46	7.42	9.23	2.86
Total Non-Current Assets	7,114.82	6,840.24	5,880.82	5,629.98	7,361.56
Inventories	2,499.83	2,373.62	2,513.05	3,028.53	3,430.78
Sundry Debtors	3,101.14	3,665.17	1,858.41	3,341.95	4,963.35
Cash and Bank	1,411.52	1,160.30	1,659.46	1,705.23	1,176.26
Other Current Assets	297.46	316.61	178.21	144.97	308.42
Short Term Loans and Advances	972.41	907.94	1,218.95	1,074.79	1,420.91
Total Current Assets	8,282.35	8,423.64	7,428.08	9,295.47	11,299.71
Net Current Assets (Including Current Investments)	3,592.92	3,877.40	1,609.50	3,328.44	4,923.28
Total Assets	15,397.17	17,565.76	13,308.90	14,925.45	18,661.26
Contingent Liabilities	361.31	336.69	1,063.30	800.26	787.81
Total Debt	3,670.35	4,347.72	990.60	2,194.20	0.00
	321.45	335.13	277.46	313.28	371.30
Adjusted Book Value	321.45	335.13	277.46	313.28	371.30

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	1,441.25	868.45	569.19	1,399.21	1,984.75
Adjustment	787.11	1,471.96	1,009.81	946.95	2,690.42
Changes In working Capital	-561.26	-1,074.48	-796.95	-2,493.63	-447.12
Cash Flow after changes in Working Capital	1,667.09	1,265.93	782.05	-147.47	4,228.04
Cash Flow from Operating Activities	1,108.65	625.39	-265.44	-827.60	3,445.03
Cash Flow from Investing Activities	-333.28	-528.49	4,560.89	2.09	-1,283.23
Cash Flow from Financing Activitie	-520.49	-77.46	-3,906.13	787.05	-2,708.75
Net Cash Inflow / Outflow	254.88	19.45	389.32	-38.46	-546.95
Opening Cash & Cash Equivalents	1,138.10	1,410.53	1,443.03	1,658.27	1,675.71
Cash & Cash Equivalent on Amalgamation / Take over / Merger		0.67
Cash & Cash Equivalent of Subsidiaries under liquidations			-191.76
Effect of Foreign Exchange Fluctuations	17.55	12.39	17.68	55.89	45.96
Closing Cash & Cash Equivalent	1,410.53	1,443.03	1,658.27	1,675.71	1,174.71

Ratios

Valuation

38.65

6.34

12.90

3.95

63.70

388.43

Profitability

14.10

20.35

8.11

13.21

3.93

Leverage & Liquidity

0.00

1.77

10.51

Returns

0.10

2.06

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	46.65	46.65	46.65	46.65	46.65	46.65	46.65	46.65	46.65
	34.94	36.30	37.40	37.80	38.30	39.38	39.33	39.67	39.53
	18.41	17.06	15.96	15.56	15.06	13.97	14.02	13.68	13.81
	53.35	53.35	53.35	53.35	53.35	53.35	53.35	53.35	53.35
No. of Shareholders	1,92,630	1,93,949	1,95,059	1,92,724	1,90,210	1,98,789	2,01,584	1,96,105	2,11,418

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-08-14	AGM
2026-07-15	Board Meeting	Quarterly Results
2026-05-29	Ex Dividend	Rs.2.5000 per share(250%)Final Dividend	2026-08-31	2026-08-31

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Glenmark Pharmaceuticals Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

11 members across the board and senior leadership

Rashmi Khandelwal

Company Secretary & Compliance Officer

—

Glenn Saldanha

Chairman & Managing Director

₹19.22 Cr

Mar '26

Anurag Mantri

Whole Time Director & Global Chief Financial Officer

₹9.72 Cr

Mar '26

Anurag Mantri

Whole Time Director & Global Chief Financial Officer

—

Cherylann Pinto

Whole Time Director & Corporate Services

₹6.54 Cr

Mar '26

B E Saldanha

Promoter & Non-Executive Director

₹6.00 L

Mar '26

Saira Ramasastry